GAITHERSBURG, Md.--(BUSINESS WIRE)--Encouraging data from GenVec, Inc.’s (Nasdaq:GNVC) Phase I clinical trial of TNFerade™ in patients with head and neck cancer were presented by study investigator Everett Vokes, M.D., University of Chicago, in a poster session at the annual meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL.
